BMO Capital Markets currently has a $6.00 price target on the $222.75 million market cap company or 48.88% upside potential. In a note released on 7 April, Black Diamond Group (TSE:BDI) stock had its “Outperform” Rating reconfirmed by stock analysts at BMO Capital Markets.
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $32.73 million. The Firm is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. It currently has negative earnings. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
Black Diamond Group Limited is a Canada company, which rents and sells modular workforce accommodation and space rental solutions to clients in Canada, the United States and Australia. The company has market cap of $222.75 million. The Firm offers lodging and other support services related to remote workforce accommodation and space rentals. It currently has negative earnings. It operates through the divisions, including Structures, Logistics, Energy Services and International.
About 118,874 shares traded. Black Diamond Group Ltd (TSE:BDI) has declined 7.36% since September 1, 2016 and is downtrending. It has underperformed by 15.86% the S&P500.
Among 7 analysts covering Black Diamond Group Ltd. (TSE:BDI), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Black Diamond Group Ltd. has $20 highest and $4.25 lowest target. $7.61’s average target is 86.06% above currents $4.09 stock price. Black Diamond Group Ltd. had 33 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Raymond James on Thursday, November 12. The rating was upgraded by BMO Capital Markets on Thursday, September 10 to “Outperform”. The stock of Black Diamond Group Ltd (TSE:BDI) has “Sector Perform” rating given on Friday, August 14 by RBC Capital Markets. The stock of Black Diamond Group Ltd (TSE:BDI) has “Sector Perform” rating given on Wednesday, November 9 by Scotia Capital. The company was maintained on Friday, August 14 by Scotia Capital. The company was upgraded on Friday, December 16 by Clarus Securities. Raymond James upgraded the shares of BDI in report on Tuesday, August 25 to “Outperform” rating. The rating was maintained by Raymond James with “Outperform” on Friday, August 14. IBC maintained it with “Underperform” rating and $5.25 target in Tuesday, March 7 report. RBC Capital Markets maintained the shares of BDI in report on Thursday, March 30 with “Sector Perform” rating.
About 350,664 shares traded or 27.14% up from the average. Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has declined 27.91% since September 1, 2016 and is downtrending. It has underperformed by 36.41% the S&P500.
Knoll Capital Management Lp holds 4.37% of its portfolio in Ampio Pharmaceuticals Inc for 2.74 million shares. Noven Financial Group Inc. owns 250,667 shares or 0.15% of their US portfolio. Moreover, Fort Point Capital Partners Llc has 0.08% invested in the company for 154,100 shares. The Colorado-based Ghp Investment Advisors Inc. has invested 0.02% in the stock. American International Group Inc, a New York-based fund reported 25,263 shares.
